Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically significant and clinically meaningful benefits to patients
SHANGHAI, July 2, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the U.S. Food and Drug Administration (FDA) has approved ZEGFROVY® (sunvozertinib) for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.
ZEGFROVY, which has received Priority Review and Breakthrough Therapy Designation from the FDA, is the only approved targeted oral treatment for NSCLC with EGFR exon20ins. This indication is approved under Accelerated Approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
"We are proud to have developed ZEGFROVY, a first-in-class oral therapy that offers a more effective treatment option with enhanced safety and ease of administration for NSCLC patients with EGFR exon20ins," said Dr. Xiaolin Zhang, CEO of Dizal. "The accelerated approval of ZEGFROVY marks a significant milestone that underscores our commitment to developing groundbreaking new medicines for patients with high unmet medical needs around the world."
ZEGFROVY is an oral, irreversible EGFR inhibitor with uniquely designed molecular structure targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. In August 2023, ZEGFROVY received accelerated approval in China. Today's FDA approval follows Breakthrough Therapy Designation and Priority Review granted by both the U.S. FDA and the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).
The FDA approval is supported by data from the multinational pivotal study WU-KONG1 Part B (WU-KONG1B), aiming to investigate the efficacy and safety of ZEGFROVY in relapsed or refractory NSCLC with EGFR exon20ins. The study results were featured as an oral presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting and were recently published in the Journal of Clinical Oncology.
"As the world's only approved targeted oral therapy for EGFR exon20ins NSCLC, ZEGFROVY has expanded the treatment paradigm in this therapeutic area that has long lacked convenient and effective treatment options," said Pasi A. Jänne, MD, PhD, Dana-Farber Cancer Institute of Harvard Medical School and lead principal investigator of WU-KONG1B. "Research findings from WU-KONG1B have demonstrated ZEGFROVY's significant therapeutic effects with consistent efficacy across both Asian and non-Asian patient populations. Its convenient once-daily oral dosing substantially improves administration convenience and patient adherence, which is an increasingly critical factor as lung cancer care shifts toward chronic disease management. The U.S. approval of ZEGFROVY® marks a landmark in scientific advancement and represents a meaningful milestone in addressing the long-standing unmet medical needs of this underserved patient population."
"ZEGFROVY has demonstrated breakthrough therapeutic value in the treatment of EGFR exon20ins NSCLC, as shown in a rigorous multinational clinical trial. Its potent antitumor activity, manageable safety profile, and convenient oral administration position it as an optimal treatment option in clinical practice," said Prof. James Chih-Hsin Yang, MD, PhD, National Taiwan University Cancer Center Hospital and the Co-lead principal investigator of WU-KONG1B. "The approval of ZEGFROVY in major global markets not only offers new hope for patients, but also reinforces our commitment to patient-centered research and the continued advancement of precision medicine in lung cancer."
"In NSCLC, EGFR exon20ins represent the third most common type of EGFR mutation. EGFR exon20ins are particularly challenging to treat due to their unique spatial conformation, diverse mutation subtypes, and high heterogeneity. As a result, patients face a poor prognosis and limited treatment options," said Prof. Mengzhao Wang, MD, PhD, lead principal investigator of the China-based pivotal study WU-KONG6 of ZEGFROVY and principal investigator of WU-KONG1B at Peking Union Medical College Hospital, "The results of the WU-KONG6 study demonstrated ZEGFROVY's clinical benefit superior to current options and lead to the drug's approval in China. The U.S. approval of ZEGFROVY will enable more patients around the world to benefit from this drug."
The FDA simultaneously approved Thermo Fisher Scientific's Oncomine™ Dx Express Test as a next-generation sequencing (NGS) companion diagnostic (CDx) for ZEGFROVY to identify NSCLC patients with EGFR Exon20 insertions. NGS testing is recognized as a critical technology in cancer genomic profiling, facilitating the rapid and precise detection of DNA mutations in tumor cells. Combined with the Ion Torrent™ Genexus™ Dx System, the test delivers NGS results in as little as 24 hours to help inform more timely treatment decisions in patients with EGFR exon20ins NSCLC.
Additionally, Dizal has completed enrollment for its multinational phase III pivotal WU-KONG28 study, evaluating ZEGFROVY versus platinum-based doublet chemotherapies in treatment naïve NSCLC patients with EGFR exon20ins across 16 countries and regions. At the 2023 European Society for Medical Oncology (ESMO) Annual Meeting, Dizal reported that ZEGFROVY, as a single oral agent, achieved a confirmed objective response rate (ORR) of 78.6% and a median progression-free survival (mPFS) of 12.4 months in the first-line setting. With its potent antitumor activity and favorable safety profile, ZEGFROVY demonstrated strong potential as an optimal first-line treatment for patients with EGFR exon20ins NSCLC.
About ZEGFROVY® (sunvozertinib)
ZEGFROVY is an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity. ZEGFROVY is approved in the U.S. and China for the treatment the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations (exon20ins), whose disease has progressed on or after platinum-based chemotherapy. The China approval is based on the results of the pivotal WU-KONG6 study in platinum-based chemotherapy pretreated NSCLC with EGFR exon20ins. The U.S. approval is supported by WU-KONG1 Part B, a multinational pivotal study investigating the efficacy and safety of ZEGFROVY in the same indication.
In addition, ZEGFROVY also demonstrated encouraging anti-tumor activity in NSCLC patients with EGFR sensitizing, T790M, and uncommon mutations (such as G719X, L861Q, etc.), as well as HER2 exon20ins.
ZEGFROVY showed a well-tolerated and manageable safety profile in the clinic. The most common drug-related TEAEs (treatment-emergent adverse event) were Grade 1/2 in nature and clinically manageable.
WU-KONG28, a phase III, multinational, randomized study assessing ZEGFROVY as a first-line treatment for patients with EGFR exon20ins NSCLC, has completed enrollment across 16 countries and regions.
Pre-clinical and clinical results of ZEGFROVY were published in peer-reviewed journals Cancer Discovery, The Lancet Respiratory Medicine and Journal of Clinical Oncology.
About Dizal
Dizal is a biopharmaceutical company, dedicated to the discovery, development and commercialization of differentiated therapeutics for the treatment of cancer and immunological diseases. The company aims to develop first-in-class and groundbreaking new medicines, and further address unmet medical needs worldwide. Deep-rooted in translational science and molecular design, it has established an internationally competitive portfolio with multiple assets in global pivotal studies and two leading assets: ZEGFROVY, approved in both the U.S. and China, and golidocitinib, approved in China. To learn more about Dizal, please visit www.dizalpharma.com, or follow us on Linkedin or Twitter.
Forward-Looking Statements
This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", and "intend" and similar expressions, as they relate to Dizal, are intended to identify certain forward-looking statements. Dizal does not intend to update these forward-looking statements regularly.
These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections, and understandings of the management of Dizal with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties, and other factors, some of which are beyond Dizal's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, Dizal's competitive environment, and political, economic, legal, and social conditions.
Dizal, the Directors, and the employees of Dizal assume (a) no obligation to correct or update the forward-looking statements contained on this site; and (b) no liability in the event that any of the forward-looking statements does not materialize or turnout to be incorrect.
Contacts
Investor Relations: ir@dizalpharma.comBusiness Development: bd@dizalpharma.comMedia Contact: pr@dizalpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/dizals-zegfrovy-sunvozertinib-receives-fda-accelerated-approval-as-the-only-targeted-oral-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302497351.html
SOURCE Dizal Pharmaceutical
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Kia Launches Killer Soul Lease Offer for July
Kia Launches Killer Soul Lease Offer for July originally appeared on Autoblog. The Kia Soul has long stood out for its playful design and clever use of space. It doesn't pretend to be a rugged SUV or a sporty hatchback—instead, it embraces its boxy charm and makes the most of it. That shape isn't just for show either. The tall roofline and upright proportions translate to real-world practicality, offering far more interior space than its modest footprint suggests. Despite being compact, the Soul has always punched above its weight in terms of passenger room and cargo flexibility. It's an ideal choice for city dwellers who want something easy to park but still roomy enough for road trips or weekend hauls. For drivers who prioritize comfort, value, and a unique aesthetic, it continues to be one of the most appealing options in its class. For July, Kia is offering a standout lease on the 2025 Soul that makes it even more compelling. Pricing starts at $259 per month for 36 months, with $3,499 due at signing, and the same monthly rate is also available for a 24-month lease, giving buyers some flexibility. These terms apply to the LX trim and assume a 10,000-mile annual limit, which should be sufficient for most drivers. The deal is available in many markets across the U.S., though pricing and availability can vary by region and dealership. For instance, around New York City and Miami, the monthly payment drops to $249, but in Dallas, customers will still have to fork over the full $259 a month. Compared to other small crossovers, the Soul's lease sits comfortably below average, especially when you factor in the up-front cost. Under the hood, the 2025 Soul comes with a 2.0-liter four-cylinder engine producing 147 horsepower, mated to a smooth CVT. It's not a powerhouse, but it handles daily driving duties with ease and delivers solid fuel efficiency. Kia estimates 30 mpg combined. Even the base LX trim is surprisingly well equipped. You get an 8-inch touchscreen, Apple CarPlay, Android Auto, and a suite of standard safety features including forward collision avoidance, lane keeping assist, and driver attention warning. The cabin materials are respectable for the price point, and the ride is quiet and composed over rough pavement. Add in excellent visibility, a comfortable driving position, and Kia's generous warranty coverage, and the Soul quickly becomes a smart pick for value-focused shoppers. The 2025 Kia Soul continues to offer a rare combination of personality, practicality, and price. While it lacks all-wheel drive and doesn't try to be sporty, it nails the basics—and now, with July's lease offer, it's easier than ever to get behind the wheel. As always, make sure to confirm with your local dealer, since pricing can shift based on your location, credit profile, and inventory. If you're in the market for a distinctive and budget-friendly ride, the Soul might just be the one.*Disclaimer: This article is provided for informational purposes only. The information presented herein is based on manufacturer-provided lease offer information, which is subject to frequent change and may vary based on location, creditworthiness, and other factors. We are not a party to any lease agreements and assume no liability for the terms, conditions, availability, or accuracy of any lease offers mentioned. All terms, including but not limited to pricing, mileage allowances, and residual values, require direct verification with an authorized local OEM dealership. This article does not constitute financial advice or an endorsement of any particular lease or vehicle. Kia Launches Killer Soul Lease Offer for July first appeared on Autoblog on Jul 4, 2025 This story was originally reported by Autoblog on Jul 4, 2025, where it first appeared.
Yahoo
an hour ago
- Yahoo
Major Burger Chain Announces a Change People Will Love
Summer is the perfect time to get outside an enjoy a fantastic burger, even though any season, really, is good for burgers. The summer season also brings late nights, because the sun is out so late, so the partying and fun tend to go into the early hours of the morning. When that burger craving hits late, there are usually limited options about what to do about it. Some grocery stores are open late, but who wants to grill a burger at midnight? Now, one major burger chain has announced a change that starts now, and it should help those who are hungry late at night. White Castle has been around for more than a century at this point. "In 1921, Billy Ingram launched a family-owned business with $700 and an idea, selling five-cent, small, square hamburgers so easy to eat, they were dubbed Sliders and sold by the sack," the company states on their website. Now, White Castle has announced expanded hours and special late-night deals to those in its loyalty program. Starting on the Summer Solstice, which was June 20 and marked the end of spring, the chain in offering new hours, branded merchandise and discounts with its Craver Nation Rewards loyalty program. According to White Castle, 91 percent of its restaurants will now be open until 1 a.m. or later, and 72 percent are open 24 hours a day. That's the most late-night hours White Castle has offered since 2020. Also, for the themed merchandise, visit White Castle's House of Crave site. "White Castle has always been there for our Cravers when it matters most — even when the clock strikes midnight and beyond," Jamie Richardson, vice president of White Castle, said in a statement. "Night Castle isn't just a moment in time — it's a state of mind. Whether it's summer nights, weekend outings or just a craving that won't quit, we're proud to be the place people turn to for craveable flavor, great value and unforgettable memories."Major Burger Chain Announces a Change People Will Love first appeared on Men's Journal on Jun 22, 2025
Yahoo
an hour ago
- Yahoo
Man Adopts a 'Fitness is Fun' Mindset and Loses 85 Pounds Playing This Trendy Game
For Ethan Noblesala, 32, a diagnosis of prediabetes and a blunt prediction from his doctor in November, 2023, motivated him to improve his health. "My doctor told me, 'If you don't change your lifestyle, you're going down a route that's leading to more surgeries, more operations and more medication,'" Noblesala tells TODAY. He says he was at his healthiest during college, but as he built his career as an entrepreneur, he neglected his health and focused on building his businesses. 'As I started that corporate lifestyle, I was slowly gaining weight,' he says. To foster business growth and connections, he was spending a lot of time at happy hours. He was lucky if he slept four hours a night. Uber Eats was the cornerstone of his diet. Exercise or even spending any time outside was practically non-existent. And his habits only got worse during COVID. His weight climbed to 235 pounds, which was a strain on his 5-foot, 6-inch frame. 'Even though I was running a successful business with my co-founder, I decided to take a leave to really focus on what was most important to me — my health,' he says. That attention to his health worked. He lost 85 pounds, and he says he feels 10 years younger. Here's how he did it. Noblesala has a background in finance, so he's motivated by numbers. He honed in on them to make changes, tracking his protein, fiber and calories. He discovered that when he ate mainly protein and fiber-dense meals, he felt satiated even when he was only eating 1,500 calories a day: 'Your body needs nutrition, but I never felt like I was starving myself or restricting myself.' He built on small goals and habit changes: Drinking a glass of water every day: 'I was 85 pounds heavier. I wasn't going to go out and run five miles, or try any of the crazy trends I see online. This was something I could do.' Shopping for groceries and checking the nutrition labels for protein, fiber and calories instead of eating out — and overeating — five times a week. Having a go-to, high-fiber, low-calorie meal that he liked to eat: Shirataki noodles with chicken breast in a low-fat buffalo sauce. Finding healthier swaps for foods he likes, such as Costco chicken nuggets instead of McDonald's: 'I found it exciting to make these new discoveries. It's something I love to do.' Noblesala grew up playing sports and loved how they kept him active while also being a way to connect with others. He'd often ask his friends if they wanted to play basketball, tennis or something else together. 'Through tennis, I discovered pickleball. That was the hook for me in terms of living a healthier and active lifestyle. I've become a pickleball fanatic,' he says. In December 2023, he joined Life Time. 'One thing I appreciate there is the community. I get to play pickleball, my favorite sport. Some people say going to the gym is a chore, but I'm excited to go." "There are endorphins you get from exercising, from being around others and from having that community," he says. "In the past, going to the gym was a solo grind, and I had to force myself to go. Now, it's not a chore. It's part of my lifestyle." Having friends at the gym and at pickleball builds accountability for him, too. 'My friends will say, 'Ethan, I'll see you tomorrow.' And, of course, then I go after work. They're expecting me,' he says. He has also joined some running clubs, such as Pitch & Run, and now he's working toward an ambitious goal — running the New York City marathon in November. He earned the opportunity to participate through his alma mater, Chaminade High School in Long Island. 'I'm nervous for the marathon because I know it's a daunting mental task. I'm focusing on the interval training and the strength training,' he says. Noblesala recognizes now how his lack of sleep was making his health worse: 'Your body needs to recover. I'm averaging six and a half to seven and a half hours of sleep a night now, and I definitely feel it when I don't get seven hours of sleep.' He's also careful about balancing his workouts with rest. He finds fitness data so valuable that he wears an Apple watch, a Whoop tracker and an Oura ring. After a day where he ran seven miles and played two hours of pickleball, he saw that his Whoop told him to take it lighter the next day. 'You can make these informed decisions with technology. It was harder to do this 10 years ago,' he says. Now that Noblesala is 85 pounds lighter and his life is centered around healthy living, he has no intention of returning to his old habits. In fact, it inspired Ethan's new company WeFit Labs, which is a gamified social fitness app designed to help motivate people to move together. If you're looking for a fitness community, join our Start TODAY walking club on Facebook and connect live with members and experts during coaching calls on the Start TODAY app! This article was originally published on
